Investor Presentation

Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story Top line growth momentum continuing into 2023 Net sales by business 9M 2023, in USD bn 6.8 1.4 +6%1 7.1 1.6 +11% +5% 5.3 5.5 9M 2022 Generics Biosimilars 9M 2023 Note: Net sales refer to net sales to third parties excluding sales to Novartis Group. Numbers may not add up due to rounding; 1. Growth vs. 9M 2022 in constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31. 21 Management Presentation Strong volume growth of 9%pts, price erosion of -3%pts below prior year Continued momentum of Generics business, driven by strong cough and cold season and contribution from recent launches Biosimilars growing double digit, with OmnitropeⓇ and HyrimozⓇ as key contributors to growth SANDOZ

View entire presentation